Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 14/20 | 1.00 |
| ▸ | FNTA | P49354 | 1/20 | 0.40 |
| ▸ | FNTB | P49356 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24835115 | 1.00 | BTN3A1 (1.00) | BTN3A1FNTAFNTB | |
| SCHEMBL10002547 | 1.00 | BTN3A1 (1.00) | BTN3A1FNTAFNTB | |
| SCHEMBL12640203 | 0.84 | BTN3A1 (1.00) | BTN3A1FNTAFNTB | |
| SCHEMBL13485653 | 0.83 | BTN3A1 (0.70) | BTN3A1 | |
| SCHEMBL20411334 | 0.82 | BTN3A1 (0.69) | BTN3A1 | |
| SCHEMBL13485450 | 0.81 | BTN3A1 (0.68) | BTN3A1 | |
| SCHEMBL18382997 | 0.79 | BTN3A1 (0.71) | BTN3A1FNTAFNTB | |
| SCHEMBL2454018 | 0.78 | BTN3A1 (0.64) | BTN3A1FNTAFNTB | |
| SCHEMBL13101858 | 0.78 | BTN3A1 (1.00) | BTN3A1FNTAFNTB | |
| SCHEMBL12640196 | 0.78 | BTN3A1 (1.00) | BTN3A1FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112054-A1 | Organophosphorous Compounds for the Activation of Gamma/Delta T Cells | BIOAGENCY AG (DE) | 2011-05-12 | — | — | US | disclosed |
| US-7871992-B2 | Organophosphorous compounds for the activation of gamma/delta T cells | BIOAGENCY AG (DE) | 2011-01-18 | — | — | US | disclosed |
| US-20080249067-A1 | Organophosphorous Compounds for the Activation of Gamma/Delta T Cells | BIOAGENCY AG (DE) | 2008-10-09 | — | — | US | disclosed |
| US-7399756-B2 | Organo-phosphorous compounds for activating gamma/delta T cells | BIOAGENCY AG (DE) | 2008-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112054-A1 | Organophosphorous Compounds for the Activation of Gamma/Delta T Cells | CD4, GZMB, PITPNB | BTN3A1 139/4885FNTA 1011/4885FNTB 157/4885 |
| US-20080249067-A1 | Organophosphorous Compounds for the Activation of Gamma/Delta T Cells | CD4, GZMB, PITPNB | BTN3A1 139/4885FNTA 1011/4885FNTB 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.